Table 4 Effectiveness of 12-week adalimumab treatment in patients with PsA stratified by prior anti-TNF therapy
| Outcome measure | No prior ETN/IFX | Prior ETN or IFX or both |
|---|---|---|
| (n = 376) | (n = 66) | |
| TJC (0 to 78) | ||
| Baseline | 16 | 15 |
| 10, 27 | 8, 25 | |
| Change, Baseline to week 12 | -10 | -10 |
| -17, -5 | -16, -3 | |
| SJC (0 to 76) | ||
| Baseline | 9 | 7 |
| 5, 13 | 5, 11 | |
| Change, Baseline to week 12 | -7 | -5 |
| -10, -3 | -8, -3 | |
| HAQ DI (0 to 3) | ||
| Baseline | 1.25 | 1.44 |
| 0.75, 1.63 | 1.00, 1.75 | |
| Change, Baseline to week 12 | -0.50 | -0.50 |
| -0.88, -0.13 | -0.75, -0.25 | |
| Patients with nail psoriasis (NAPSI ≥ 1) | n = 223 | n = 36 |
| NAPSI (0 to 80) | ||
| Baseline | 14 | 18 |
| 5, 30 | 10, 37 | |
| Change, Baseline to week 12 | -6 | -6 |
| -14, -2 | -15, -1 |